The state area of the country and the country area of the country and the country area of the country and the country are country and the country area of the country are considered as a country are

PTO/SB/05 (2/98)
Approved for use through 09/30/2000, OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

## UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 3TC FR §1.53(s))

APPLICATION ELEMENTS

Attorney Docket No. PC10934AGPR

First Named Inventor or Application Identifier Richard John Bazi

Title Crystal Structure

Express Mail Label No. EL911725549US

See MPEP chapter 600 concerning utility patent application contents.					Box Patent Application Washington, DC 20231					
1.	*Fee Transmittal Form (e.g., PTO/SB/17) Submit an original, and a duplicate for fee processing)			6.	6. Microfiche Computer Program (Appendix)					
2.	Specification [Total Pages (preferred arrangement set forth below) [462]					Jucleotide and/or Amino Acid Sequence Submission if applicable, all necessary)				
		title of the Invention	-Unations		a.	$\boxtimes$	Computer Rea	dable C	ору	
		erences to Related Ap Regarding Fed spons			b.	$\boxtimes$	Paper Copy (ic	lentical 1	to computer copy)	
		in Microfiche Appendi			c.	$\boxtimes$	Statement veri	fvina ida	entity of above copie	
	- Backgroun	d of the Invention		_	ACCOMPANYING APPLICATION PARTS					,,,
	- Brief Summary of the Invention			8.	$\square$					
	Brief Description of the Drawings (if file     Detailed Description		(if filed)						et & document(s))	
	<ul> <li>Detailed Description</li> <li>Claim(s)</li> </ul>			9.			§3.73(b) State		Power of At	torney
		the Disclosure		l			here is an assi			
*				10.	$\sqcup$	English	Translation Do	cument	(if applicable)	
3.	Drawing(s) (35	U.S.C. 11.3)[Total sh		11.	Ш		tion Disclosure ent (IDS)/PTO-	1449	Copies of IE Citations	S
4.	Oath or Declaration [Total pages 3			12.	П	Prelimin	ary Amendmer	nt		
	a. Newly executed (original or copy)			13.	$\square$	Return f	Receipt Postca	m (MPF	P 503)	
	b. Copy from a prior application (37 CFR						be specifically			
	§1,63(c		1 (07 01 1)	14.		*Small E	Entity	Stateme	ent filed in prior app	lication
	(for con	tinuation/divisional with E [Note Box 5 b			_	Stateme	, –		till proper and desire	
	i.	DELETION OF IN		15.	$\boxtimes$	Certified	Copy of Priori	y Docui	ment(s)	
		d statement attached or or (s) named in the price		1	_	(if foreig	n priority is cla	med)	` '	
		C.F.R. §§1.63(d)(2)		ı						
5.		By Reference (useable		14.	$\boxtimes$	Other:	Priority Clai	m		
The ent	lire disclosure	of the prior application	, from which a				-			
copy of	the oath or de	claration is supplied u of the disclosure of the	nder Box 4b, is	l	U.K. Provisional Application No. 0030 filed December 13, 2000 and U.S. Pr					
		by incorporated by re					Application		260,627, filed Janua	
							2001.			
					*NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).					
47 K - 0	OUT IN IN IO A			IF ON	E FILED I	N A PRIOR	APPLICATION IS	RELIED UP	PON (37 C.F.R. § 1.28).	
		PPLICATION, check a								
Щ	Continuation	Divisional	Continuation	n-in-pa	rt (CIP)		of prior applica	tion No:		
Prior a	application info	rmation: Exam	iner				Group/A	rt Unit:		
		1:	CORRES	POND	ENCE	ADDE				
(Inpart Customor No. or Attach has only Istal has)										
Correspondence address below										
Name										
Address Pfizer Inc.										
Address Patent Department, MS 4159, Eastern Point Road										
City Groton		State	C	т		Zıp Cod	ip Code 06340			
Country	, in the production		Telephone		(860)-44		Fax	1-	-(86C)-441-5221	
			Regis	Registration No. (Attorney/Agent) 36,647			47			
Signature Dung Kegmis						D.	ate	12	13/01	
		190	<b>#</b>							

PTO/SB/17(2/98) Approved for use through 98/30/2000
OMB 9851-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Complete if Known FEE TRANSMITTAL Application Number To be assigned Filing Date Concurrently Herewith Patent fees are subject to annual revision on October 1. First Named Inventor Richard John Bazin These are the fees effective October 1,. 2001. Entity payments must be supported by a small entity statement, Examiner Name To be assigned nerwise large entity fees must be paid. See Forms PTO/SB/09-12. Group/Art Unit See 37 C.F.R. §§ 1.27 and 1.28 To be assigned otal Amount of Payment (\$)1.038.00 Attorney Docket No PC109344GPR METHOD OF PAYMENT (check one) FEE CALCULATION (conti-The commissioner is hereby authorized to charge ADDITIONAL FEES indicated fees and credit any over payments to: Large Entity Small Entity Account 16-1445 Code (\$) Code 1\$1 Fee Description Fee Paid Deposit 105 130 205 65 Surcharge - late fee or oath Account Pfizer Inc. Name 127 50 227 25 Surcharge-late provisional filing fee or Charge Any Additional Charge the Issue Fee Set in 37 C.F.R. § 1.1.8 at the Mailing cover sheet 37 Fee Required Under 139 130 139 130 Non-English specification C.F.R. §§ 1.1.6 and 1.17. of the Notice of Allowance 147 2,520 147 2.520 For filing a request for reexamination Payment Enclosed: 112 920 112 9201 Requesting publication of SIR prior to Examiner action Check Money Order ☐ Other 113 1.840\* 113 1,840\* Requesting publication of SIR after Examiner action FEE CALCULATION 115 110 215 55 Extension for reply within first month CBASIC FILING FEE 116 400 216 200 Extension for reply within second month 117 920 217 460 Large Entity Extension for reply within third month Small Entity Fee Description Fee Paid 118 1,440 218 720 Extension for reply within fourth month Code (\$) Code (\$) 128 1.960 228 1191 740 201 370 Utility filing fee 740 00 980 Extension for reply within fifth month 306 330 206 165 Design filing fee 119 320 219 160 Notice of Appeal 107 510 207 255 Plant filing fee 120 320 220 160 Filling a brief in support of an appeal 108 740 208 370 Reissue filing fee 121 280 221 140 Request for oral hearing 194 160 214 80 Provisional filling fee 138 1.510 138 1,510 Petition to institute a public use proceeding 740.00 SUBTOTAL (1) (\$) 140 110 240 55 Petition to revive - unavoidable 2. EXTRA CLAIM FEES 141 1.280 241 640 Petition to revive - unintentional Extra Fee from 142 1,280 242 640 Utility issue fee (or reissue) Claims Fee Paid below Total Claims > 18 00 143 460 243 230 Design issue fee 144 620 244 310 5 84.00 Plant issue fee 168 00 Multiple Dependent 122 130 122 130 Petitions to the Commissioner or number previously paid, if greater; For Reissues, see below 123 50 123 50 Petitions related to provisional Small Entity Large Entity applications Fee Fee Fee Fee Fee Description Submission of Information Disclosure 126 180 126 180 Code (\$) Code (\$) Statement 103 18 203 g Claims in excess of 20 581 40 581 40 Recording each patent assignment per 40 00 property (times number of properties) 102 84 202 42 Independent claims in excess of 3 146 740 246 370 Filing a submission after final rejection (37 CFR 1.129(a)) 104 280 204 140 Multiple dependent claim, if not paid 149 740 249 370 For each additional invention to be examined (37 CFR 1 129(b))

Other Fee (specify)

Other Fee (specify)

\*Reduced by Basic Filing Fee Paid

12/13/01

SUBTOTAL (3) (\$)

24

Complete (if Applicable)

Reg Number

User ID

Deposit Account

40.00

			,	
Express	Mail No.	EL911	1725549U	S

\*\*Reissue independent claims over

"Reissue claims in excess of 20 and

258.00

onginal paten

over original patent SUBTOTAL (2) (\$)

100 84 209 42

110 18 210

Signature

SUBMITTED BY

Type or Printed Name

I hereby	certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed
to: Box	SEQUENCE, Director – U.S. Patent and Trademark Office, Washington, D.C. 20231 on this 13th day of December, 2001.
	2
By	Dlama L. Miller
	(Signature of person mailing)
	Deanna L. Miller
	(Typed or printed name of person)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Richard John Bazin, et al :

APPLICATION NO.: To be assigned : Examiner: To be assigned FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: Crystal Structure :

Box SEQUENCE Director – U.S. Patent and Trademark Office Washington, D.C. 20231

## STATEMENT REGARDING SUBMISSION OF SEQUENCE LISTING UNDER 37 C.F.R. §1.821(f)

I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

Respectfully submitted,

Date: 12 13 01

Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746